INAB logo

IN8BIO INC

INABNASDAQ
🏆 #4944 by market capUS Equity
$355.18▲ $16.69 (+4.70%)
Simulated price
🔔
Track INAB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair
No chart data available for INAB.

Trading Snapshot

Day Range
$349.70 – $356.86
52-Week Range
$0.88 – $2.73
Volume
$1.82B
Avg Volume
$1.32B
Shares Outstanding
9.6M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$841,779
P/E Ratio
-0.7
P/S Ratio
0.0x
EPS (TTM)
$-0.96
Dividend Yield
0.00%
Dilution (1yr)
+304.2%

Why Investors Own INAB

  • ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 53% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INAB logo

IN8BIO INC

INAB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▼ −34.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▼ −47.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.8M▲ +304.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$18M YoY
StockOtter · stockotter.space

About IN8BIO INC

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$373.64
▲ +5.2% Upside
High Target$468.77
Low Target$292.00
Based on 9 analysts

Latest News & Updates

🚀
Barron’s·2h ago

IN8BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift INAB price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

IN8BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.